Prevention of Withdrawal in Pediatric Patients Receiving Long-term Dexmedetomidine Infusions

dc.contributor.authorBerrens, Zachary J.
dc.contributor.authorSauro, Ashley L.
dc.contributor.authorTillman, Emma M.
dc.contributor.departmentPediatrics, School of Medicine
dc.date.accessioned2024-08-15T07:32:23Z
dc.date.available2024-08-15T07:32:23Z
dc.date.issued2021
dc.description.abstractObjective: Determine if the addition of clonidine was associated with a decreased incidence of dexmedetomidine withdrawal in patients who received prolonged dexmedetomidine infusions. Methods: This was a retrospective observational cohort study conducted at a single-center PICU in an academic children's hospital. Children 1 month to 18 years of age who received dexmedetomidine infusion for 5 days or longer were included in the study. Results: Fifty patients met the inclusion criteria with 15 patients who received clonidine and 35 who received a dexmedetomidine wean alone. Withdrawal criteria included blood pressure changes, heart rate changes, and documented agitation. Overall, there was no difference in change in blood pressure or documented agitation between groups. Patients who did not receive clonidine had a greater number of heart rate readings above normal for age following discontinuation of the infusion, yet this was not statistically significant. Potentially more importantly, the addition of clonidine did not impact the duration of dexmedetomidine wean or the PICU length of stay after dexmedetomidine discontinuation. Conclusions: The addition of clonidine while weaning a long-term dexmedetomidine infusion did not lead to lower blood pressures or agitation, but did lead to decreased percentage of heart rates above the age-appropriate range. The clinical significance of this is unknown, and further investigation is warranted. The addition of clonidine did not decrease time to weaning off dexmedetomidine or shorten PICU length of stay.
dc.eprint.versionFinal published version
dc.identifier.citationBerrens ZJ, Sauro AL, Tillman EM. Prevention of Withdrawal in Pediatric Patients Receiving Long-term Dexmedetomidine Infusions. J Pediatr Pharmacol Ther. 2021;26(1):81-86. doi:10.5863/1551-6776-26.1.81
dc.identifier.urihttps://hdl.handle.net/1805/42787
dc.language.isoen_US
dc.publisherAllen Press
dc.relation.isversionof10.5863/1551-6776-26.1.81
dc.relation.journalJournal of Pediatric Pharmacology and Therapeutics
dc.rightsPublisher Policy
dc.sourcePMC
dc.subjectAdrenergic alpha-2 receptor agonists
dc.subjectChild
dc.subjectClonidine
dc.subjectCritical care
dc.subjectDexmedetomidine
dc.subjectWithdrawal
dc.titlePrevention of Withdrawal in Pediatric Patients Receiving Long-term Dexmedetomidine Infusions
dc.typeArticle
ul.alternative.fulltexthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792144/
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Berrens2021Prevention-PP.pdf
Size:
110.91 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: